CYCS and neoplasm: Further studies might explore additional inflammation markers like prostaglandin E2 (PGE2), nitric oxide (NO), interleukin-1 beta (IL-1β), and tumor progression through flow cytometry, angiogenesis markers such as vascular endothelial growth factor (VEGF), and apoptosis-related markers including caspase-8, cytochrome C release, and PARP cleavage.